Tesamorelin Reconstitution Calculator

Tesamorelin is a stabilized analog of GHRH (growth hormone–releasing hormone) — a 44-amino-acid peptide with a chemical modification that makes it last longer in the body. It binds the pituitary's GHRH receptor to trigger natural pulses of your own growth hormone, which then raises IGF-1; it is not a steroid and not growth hormone itself. It's notable as the only FDA-approved GHRH analog, sold as Egrifta / Egrifta SV.

The FDA-approved regimen is a once-daily subcutaneous injection into the abdomen; the long-standing labeled dose is 2 mg per day (the newer Egrifta SV delivers an equivalent 1.4 mg in 0.35 mL). No — you do not have to be asleep for it to work; the peptide triggers a GH pulse whenever you inject it. Some clinicians suggest bedtime dosing to line up with your natural overnight GH surge, but consistency matters more than the exact hour, and these specifics should come from a prescriber.

Add bacteriostatic water to the dry vial slowly and swirl gently — don't shake. For example, a 10 mg vial + 2 mL of water gives 5 mg/mL, so a 2 mg dose is 0.4 mL, which is 40 units on a U-100 insulin syringe. Note that tesamorelin is dosed in milligrams, not the micrograms used for GHRPs — so the volumes are larger and easier to draw. Use the calculator above for your exact vial size and target dose.

Tesamorelin's defining, FDA-approved effect is reducing visceral fat — the deep fat around the organs — specifically in HIV-associated lipodystrophy; it also lowers fat in the liver. Importantly, it is weight-neutral and not approved as a general weight-loss drug: it reshapes where fat sits more than it drops the number on the scale, and it doesn't target the subcutaneous fat just under the skin. That's also why its mechanism differs from GLP-1-class drugs like retatrutide — tesamorelin works by amplifying your own growth hormone rather than acting on appetite, and any combination is a clinical decision, not a calculator one.

Tesamorelin isn't known to cause cancer, but because it raises IGF-1 its FDA label lists active cancer (any type) as a contraindication, along with pregnancy and allergy to tesamorelin or mannitol — and its long-term cardiovascular safety has not been established. Commonly reported effects are joint aches, injection-site reactions, swelling in the limbs, and muscle pain. On storage, the approved Egrifta SV is kept at room temperature before mixing and used immediately once reconstituted, whereas research-grade lyophilized tesamorelin is usually refrigerated, kept out of light, and used within weeks after reconstitution — always follow your specific product's instructions. It is a prescription drug for its approved use and is banned by WADA in sport.